Baird and Goldman Sachs Lower Mirion Technologies, Inc. (MIR) Price Target But Stay Bullish

Core Insights - Mirion Technologies, Inc. (NYSE:MIR) is recognized as a promising investment by hedge funds, despite recent price target reductions from major firms [1][2] Group 1: Financial Performance - Baird lowered its price target on Mirion from $30 to $29 while maintaining an Outperform rating, citing strong performance in the nuclear segment as a highlight [1] - Goldman Sachs reduced its price target from $33 to $29 but kept a Buy rating, noting Q4 adjusted EBITDA of $77.6 million, an 11.5% increase from $69.6 million in the same period in 2024, driven by strong margins in the Medical segment [2] - The company achieved over $400 million in orders for the first time, indicating robust demand [2] Group 2: Market Outlook - Despite a decline in stock value due to weaker organic growth and guidance suggesting improved performance in the second half of 2026, Goldman Sachs maintains a positive outlook for the Nuclear segment, presenting a potential buying opportunity [3] - Mirion Technologies is a global leader in radiation safety, providing solutions across various sectors including nuclear, medical, defense, and research [4]